Novartis Japan Conflict Of Interest Regarding Diovan Leads To Employee Training
This article was originally published in PharmAsia News
Executive Summary
Novartis will suspend all promotion of drugs July 1-5 in Japan as it holds training on conflicts of interest and compliance in response to issues related to physician-led clinical trials at Novartis Japan with Diovan (valsartan).